Cover Image

EU5個國家的醫療事務 (MA) 評估:非小細胞肺癌 (NSCLC)

Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018

出版商 FirstWord 商品編碼 488076
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
EU5個國家的醫療事務 (MA) 評估:非小細胞肺癌 (NSCLC) Medical Affairs Reputations: Non-Small Cell Lung Carcinoma (EU5) 2018
出版日期: 2018年02月01日 內容資訊: 英文

本報告依據處理非小細胞肺癌治療藥的主要11項產品的各公司醫療事務 (MA) 團隊相關150名歐盟5國的腫瘤專門醫生的調查結果,提供各公司團隊的效能及滿意度的評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析彙整。


  • Avastin (Bevacizumab:Roche)
  • Cyramza (Ramucirumab:Eli Lilly)
  • Gilotrif (Afatinib:Boehringer Ingelheim)
  • Iressa (Gefitinib:AstraZeneca)
  • Keytruda (Pembrolizumab:Merck Sharp & Dohme)
  • Opdivo (Nivolumab:Bristol-Myers Squibb)
  • Tagrisso (Osimertinib:AstraZeneca)
  • Tarceva (Erlotinib:Roche)
  • Tecentriq (Atezolizumab:Roche)
  • Xalkori (Crizotinib:Pfizer/Merck Group)
  • Zykadia (Ceritinib:Novartis)


  • 醫生的需求
    • 醫生的MA團隊的利用方法、頻率
    • 認為最重要的服務
    • 最適合的聯繫頻率和途徑
  • MA團隊提供的內容
    • 醫生與團隊的互動印象
    • 醫生的團隊效能、滿意度排行榜:12項
    • 與其他團隊的比較
  • 改善需要的地方

第1章 調查目的,調查手法,取樣調查法,摘要整理

第2章 不同的跟MA團隊的聯絡情形

  • 跟每個產品的MA團隊的聯絡 (過去6個月)
  • 跟每個產品的MA團隊的聯絡頻率 (現在)

第3章 對MA團隊的各種屬性效能的競爭評估

  • 跟各產品的MA團隊的聯絡的全體品質的評估
  • 對醫生的業務,MA團隊所扮演的角色的屬性的重要性
  • EdgeMap分析:對MA團隊的屬性的效能的競爭評估
  • 跟MA團隊的聯絡相關醫生的滿意度的競爭評估
  • 需求差距分析:各產品

第4章 推薦的聯絡媒體,頻率,改善提案

  • 推薦的聯絡媒體,頻率,改善提案

第5章 附錄



Compare 11 NSCLC medical affairs teams. See how your team stacks up to the market leader

In the EU5, several of the NSCLC medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 medical oncologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?

Discover all the ways you can improve your medical affair services in Medical Affairs Reputations: NSCLC (EU5). Comparing 11 major NSCLC treatments from Roche, Eli Lilly, AstraZeneca, Merck Sharp & Dohme, BMS, Novartis, and Pfizer, this detailed report reveals:

  • How medical oncologists rate your team overall, and on 12 key medical affairs services.
  • Which medical affairs services are most important.
  • How, and how often medical oncologists want to meet with your team.
  • What you can do to improve your medical affairs services.

It's time to find out exactly how well your medical affairs team is performing against fierce competition - and establish an action plan to gain competitive advantage.

Top Takeaways

  • All to play for at the top, limited options at the bottom. Only 3 points separate the top 2 leading brands in terms of overall quality of interactions, whereas brands at the bottom could struggle to make up ground.
  • Information is the #1 priority. The most important medical affairs services all relate to providing information that doctors can use to make better treatment decisions.
  • Huge variations in activity. In the past six months, only 2 of the 13 teams interacted with more than 70% of doctors surveyed, and the least active teams saw no more than 53% of them.
  • Doctors want to see teams in-person and not too often. The report reveals how, and how frequently your team should engage.
  • Digital interaction still some way off becoming the norm. For the most part, doctors want personal interactions, not emails or phone calls.

Insight into Medical Affairs Teams for These 12 NSCLC Treatments

  • Avastin (bevacizumab; Roche)
  • Cyramza (ramucirumab; Eli Lilly)
  • Giotrif (afatinib; Boehringer Ingelheim)
  • Iressa (gefitinib; AstraZeneca)
  • Keytruda (pembrolizumab; Merck Sharp & Dohme)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tagrisso (osimertinib; AstraZeneca)
  • Tarceva (erlotinib; Roche)
  • Tecentriq (atezolizumab; Roche)
  • Xalkori (crizotinib; Pfizer)
  • Zykadia (ceritinib; Novartis)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 11 medical affairs teams-answering important questions like:

What do physicians need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Doctors

We surveyed 150 medical oncologists from the EU5 (France, Italy, Germany, Spain, UK) - chosen from the largest community of validated physicians in the world

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC ina typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the past 6 months.

We conducted the survey between February 6-12, 2018.

Money Back Guarantee!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

Table of Contents

1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary

2. Current Status of Interactions with Different Medical Affairs Teams

  • 2.1. Interactions in the past 6 months with Medical Affairs teams for each product
  • 2.2. Current frequency of interactions with medical affair teams for each product

3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes

  • 3.1. Evaluation of overall quality of interactions with Medical Affairs teams for each product
  • 3.2. Attribute importance of Medical Affairs teams roles to physicians' practice
  • 3.3. EdgeMap analysis - Competitive evaluation on Medical Affairs teams performance on attributes
  • 3.4. Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
  • 3.5. Need-Gap analysis by product

4. Preferred Interaction Media, Frequency, and Suggestions for Improvement

  • 4.1. Preferred interaction media and frequency, and suggestions for improvement

5. Appendix

Back to Top